LNPs, having undergone extensive research, represent the most advanced non‐viral gene delivery systems and are less immunogenic than viral vectors.[6] In 2013, RNA interference (RNAi) therapy using anti‐vascular endothelial growth factor (anti‐VEGF) and anti‐Kinesin spindle proteins (anti‐KSP) siRNAs delivered by LNPs was first evaluated in HCC patients. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.